TH07 - A New Novel Topical Treatment for Androgenic Alopecia

Area of Science:

• Dermatology
• Pharmacology
• Hair Restoration Science

Background:

• Androgenic alopecia (AGA) affects many men, with current treatments like topical minoxidil and oral finasteride having limitations.
• Finasteride can cause systemic adverse events, and neither approved treatment is fully effective for all patients.
• A novel combination topical therapy, TH07 (finasteride, latanoprost, minoxidil), has been developed to potentially improve AGA treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy of the novel topical combination therapy TH07 for androgenic alopecia (AGA).
• To compare the effectiveness of TH07 against its individual components (finasteride, latanoprost, minoxidil) as monotherapy.
• To assess patient satisfaction and safety profile of TH07 in men with AGA.

Main Methods:

• A 6-month, randomized, proof-of-concept study involving patients with light to moderate AGA.
• Participants were treated once daily with either TH07, 0.1% finasteride, 0.03% latanoprost, or 5% minoxidil.
• Efficacy was assessed by investigator evaluation of photographic evidence and patient self-reported outcomes and satisfaction.

Main Results:

• Investigators observed moderate hair regrowth in the majority of patients treated with TH07, outperforming monotherapy treatments.
• Most patients using TH07 reported higher satisfaction with their hair appearance compared to those using individual components.
• The TH07 regimen was well-tolerated, with no reported systemic adverse events during the study period.

Conclusions:

• Topical TH07 demonstrates superior efficacy in treating androgenic alopecia (AGA) compared to its individual active ingredients.
• The combination therapy offers a promising, safe, and well-tolerated alternative for managing male pattern hair loss.
• TH07 represents a potential advancement in topical treatments for AGA, addressing unmet needs in hair restoration.